Cargando…

Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles

Mucopolysaccharidosis type II (MPSII) is a lysosomal storage disorder due to the deficit of the enzyme iduronate 2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans in most organ-systems, including the brain, and resulting in neurological involvement in about two-thirds of the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rigon, Laura, Salvalaio, Marika, Pederzoli, Francesca, Legnini, Elisa, Duskey, Jason Thomas, D’Avanzo, Francesca, De Filippis, Concetta, Ruozi, Barbara, Marin, Oriano, Vandelli, Maria Angela, Ottonelli, Ilaria, Scarpa, Maurizio, Tosi, Giovanni, Tomanin, Rosella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514713/ https://www.ncbi.nlm.nih.gov/pubmed/31022913 http://dx.doi.org/10.3390/ijms20082014

Ejemplares similares

Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders
por: Salvalaio, Marika, et al.
Publicado: (2016)

Glial degeneration with oxidative damage drives neuronal demise in MPSII disease
por: Zalfa, Cristina, et al.
Publicado: (2016)

Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model
por: Salvalaio, Marika, et al.
Publicado: (2017)

Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment
por: Mazzoccoli, Gianluigi, et al.
Publicado: (2013)

Mucopolysaccharidosis Type VI, an Updated Overview of the Disease
por: D’Avanzo, Francesca, et al.
Publicado: (2021)

Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy
por: Maccari, Francesca, et al.
Publicado: (2022)

Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment
por: D’Avanzo, Francesca, et al.
Publicado: (2020)

Quantitative comparison of the protein corona of nanoparticles with different matrices
por: Ottonelli, Ilaria, et al.
Publicado: (2022)

Corrigendum to “Quantitative comparison of the protein corona of nanoparticles with different matrices” [Int J Pharm X 2022 Oct 21;4: 100136]
por: Ottonelli, Ilaria, et al.
Publicado: (2023)

A novel CRISPR/Cas9-based iduronate-2-sulfatase (IDS) knockout human neuronal cell line reveals earliest pathological changes
por: Badenetti, Lorenzo, et al.
Publicado: (2023)

Tween(®) Preserves Enzyme Activity and Stability in PLGA Nanoparticles
por: Duskey, Jason Thomas, et al.
Publicado: (2021)

Investigating Novel Syntheses of a Series of Unique Hybrid PLGA-Chitosan Polymers for Potential Therapeutic Delivery Applications
por: Duskey, Jason Thomas, et al.
Publicado: (2020)

Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles
por: Vilella, Antonietta, et al.
Publicado: (2015)

Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans—A Diagnostic Prediction Model
por: D’Avanzo, Francesca, et al.
Publicado: (2023)

Tunneling Nanotubes: A New Target for Nanomedicine?
por: Ottonelli, Ilaria, et al.
Publicado: (2022)

Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study
por: Zanetti, Alessandra, et al.
Publicado: (2019)

PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study
por: Hoyos-Ceballos, Gina P., et al.
Publicado: (2020)

Recent Advances on Surface-Modified GBM Targeted Nanoparticles: Targeting Strategies and Surface Characterization
por: Rodà, Francesca, et al.
Publicado: (2023)

Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function
por: Duskey, Jason Thomas, et al.
Publicado: (2020)

Nanomedicine against Aβ Aggregation by β–Sheet Breaker Peptide Delivery: In Vitro Evidence
por: Pederzoli, Francesca, et al.
Publicado: (2019)

Exploiting the Potential of Drosophila Models in Lysosomal Storage Disorders: Pathological Mechanisms and Drug Discovery
por: Rigon, Laura, et al.
Publicado: (2021)

Drosophila D-idua Reduction Mimics Mucopolysaccharidosis Type I Disease-Related Phenotypes
por: De Filippis, Concetta, et al.
Publicado: (2021)

Optimization of an Injectable Hydrogel Depot System for the Controlled Release of Retinal-Targeted Hybrid Nanoparticles
por: Ottonelli, Ilaria, et al.
Publicado: (2022)

Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study
por: Sestito, Simona, et al.
Publicado: (2022)

Microfluidic Technology for the Production of Hybrid Nanomedicines
por: Ottonelli, Ilaria, et al.
Publicado: (2021)

Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments
por: Duskey, Jason Thomas, et al.
Publicado: (2022)

Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years
por: Tomanin, Rosella, et al.
Publicado: (2014)

Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy
por: Polito, Vinicia Assunta, et al.
Publicado: (2010)

Case report of endoprosthesis -Y implantation in severe respiratory failure in the MPSII patient; comparison with literature data
por: Gocyk, Wojciech, et al.
Publicado: (2020)

“Combo” Multi-Target Pharmacological Therapy and New Formulations to Reduce Inflammation and Improve Endogenous Remyelination in Traumatic Spinal Cord Injury
por: Moretti, Marzia, et al.
Publicado: (2023)

Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy
por: Ellison, Stuart, et al.
Publicado: (2023)

Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved
por: Fusar Poli, E, et al.
Publicado: (2013)

QueryOR: a comprehensive web platform for genetic variant analysis and prioritization
por: Bertoldi, Loris, et al.
Publicado: (2017)

Detection of PLGA-based nanoparticles at a single-cell level by synchrotron radiation FTIR spectromicroscopy and correlation with X-ray fluorescence microscopy
por: Pascolo, Lorella, et al.
Publicado: (2014)

Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases
por: Scarpa, Maurizio, et al.
Publicado: (2011)

Applications of the ROS-Responsive Thioketal Linker for the Production of Smart Nanomedicines
por: Rinaldi, Arianna, et al.
Publicado: (2022)

Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know
por: Filocamo, Mirella, et al.
Publicado: (2018)

Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment
por: Oddone, Natalia, et al.
Publicado: (2020)

Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants
por: Zanetti, Alessandra, et al.
Publicado: (2021)

Post–Vision and Change: Do We Know How to Change?
por: D’Avanzo, Charlene
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uh8i5rg9nnskv030kfrfmead4k